ABTECT-2
49 evidence topics · 9 sources
Objective
Primary objectives for the FDA and for the EMA in the protocol
Place of the trial in the phase 3 development plan
Main objective in the EU Clinical Trials Information System record
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2023-01-25” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2025-06-24” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2025-07-15” (opens the source at this quote in a new tab)
“First Posted 2022-08-18” (opens the source at this quote in a new tab)
“Results First Posted 2026-09-10” (opens the source at this quote in a new tab)
“Last Update Posted 2026-09-10” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Planned number of sites and potential countries in the protocol
EU member states and trial dates in the EU Clinical Trials Information System record
Sites and countries of the two induction trials stated by the company
Study design
Periods, randomization ratio, and planned arm sizes in the protocol
Randomization stratification factors, including region
Endoscopy, central reading, and electronic diaries
Rationale for the 8-week treatment duration in the protocol
Eligibility criteria
Key inclusion criteria in the ClinicalTrials.gov record
Key exclusion criteria in the ClinicalTrials.gov record
Minimum age by region in the protocol
Age range in the EU Clinical Trials Information System record
Eligibility summarized in the late-breaking abstract
“The multicenter, randomized, double‐blind, placebo‐controlled ABTECT trials enrolled pts with moderate‐to‐severe UC (defined as modified Mayo score (MMS) ≥ 5, with rectal bleeding sub‐score (RBS) ≥ 1 and centrally read endoscopic score ≥ 2) who had inadequate response, loss of response, or intolerance to at least one prior therapy (with no upper limit), including corticosteroids, immunosuppressants, biologics, S1P receptor modulators and/or JAK inhibitors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Arms and administration in the ClinicalTrials.gov record
Capsule strengths and dosing instructions in the protocol
Background ulcerative colitis therapy allowed during the trial
Study outcomes
Rationale for using clinical remission by modified mayo score as the primary endpoint
Primary endpoint and its definition in the ClinicalTrials.gov record
FDA recommendation of clinical remission by the modified Mayo Score as the primary endpoint
Co-primary endpoints for the EMA and key secondary endpoints for the FDA
Secondary endpoint definitions in the ClinicalTrials.gov record
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size in the protocol
Actual enrollment in the ClinicalTrials.gov record
Participants analyzed by arm in the posted results
| Population | ABX464 50 mg | ABX464 25 mg | Placebo | Total |
|---|---|---|---|---|
| Started | “318” | “159” | “159” | Not reported |
| Baseline | “318” | “159” | “159” | “636” |
| Adverse events (at risk) | “0/318 (0.00%)” | “0/159 (0.00%)” | “0/159 (0.00%)” | Not reported |
Participants randomized and treated in the late-breaking abstract
Description of analysis sets
Analysis population in the posted results
Analysis sets in the statistical analysis plan
Primary analysis method, region factor, and testing sequence in the protocol
Handling of intercurrent events and missing data in the statistical analysis plan
Consequence of the 25 mg primary endpoint result for the testing hierarchy
“Hierarchical testing strategy was used starting with 50 mg for the primary endpoint followed by the key secondary endpoints; the 25 mg was subsequently tested for the primary endpoint followed by the key secondary endpoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“25 mg did not meet the primary endpoint at week 8 in ABTECT‐2 in the FDA testing protocol, therefore p ‐values for key secondary endpoints for the 25 mg arm in ABTECT‐2 are nominal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Baseline characteristics
Baseline characteristics by arm in the posted results
| Characteristic | ABX464 50 mg (n=318) | ABX464 25 mg (n=159) | Placebo (n=159) | Total (n=636) |
|---|---|---|---|---|
| Age, years, mean (SD) | “41.4(13.64)” | “41.3(12.83)” | “41.6(14.68)” | “41.4(13.69)” |
| Age 65 years or older, participants | “19” | “6” | “16” | “41” |
| Female, participants | “138” | “60” | “58” | “256” |
| Male, participants | “180” | “99” | “101” | “380” |
| Asian, participants | “66” | “29” | “39” | “134” |
| Black or African American, participants | “6” | “3” | “4” | “13” |
| White, participants | “231” | “116” | “108” | “455” |
| Weight, kg, mean (SD) | “71.75(17.101)” | “73.37(16.050)” | “73.91(17.387)” | “72.69(16.919)” |
| Duration of ulcerative colitis, years, mean (SD) | “7.74(7.193)” | “7.92(6.769)” | “7.75(6.503)” | “7.79(6.911)” |
| At least one prior advanced therapy inadequate response, participants | “159” | “76” | “79” | “314” |
| Inadequate response to JAK inhibitors among those with AT-IR, participants | “33” | “19” | “20” | “72” |
| Modified Mayo Score, mean (SD) | “6.9(1.11)” | “7.0(1.04)” | “6.8(0.98)” | “6.9(1.06)” |
| Mayo endoscopic subscore 2, participants | “130” | “56” | “64” | “250” |
| Mayo endoscopic subscore 3, participants | “188” | “103” | “95” | “386” |
| Fecal calprotectin, µg/g, mean (SD) | “3759.05(7548.48)” | “4121.86(7081.92)” | “4499.81(8074.99)” | “4038.06(7569.95)” |
Disease severity of the 25 mg group compared with ABTECT-1 stated by the company
Proportion with prior advanced therapy inadequate response in the late-breaking abstract
“Among pts who participated in ABTECT‐1, ABTECT‐2, and the pooled analysis, 45.3% (288/636), 49.4% (314/636), and 47.3% (602/1272) were AT‐IR‐Yes, respectively; 54.7% (348/636), 50.6% (322/636), 52.7% (670/1272) were AT‐IR‐No.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Primary and key secondary endpoints at Week 8
“25 mg did not meet the primary endpoint at week 8 in ABTECT‐2 in the FDA testing protocol, therefore p ‐values for key secondary endpoints for the 25 mg arm in ABTECT‐2 are nominal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Endoscopic improvement/symptomatic remission were co‐primary endpoints for the EMA protocol and were met by both doses in both trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants meeting each endpoint at Week 8 in the posted results
Primary endpoint result for the 25 mg dose stated by the company
Subgroups by prior advanced therapy inadequate response at Week 8 (nominal p-values)
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-emergent adverse events at Week 8 reported by the company
| Event, n (%) | Placebo (N=159) | Obefazimod 25 mg (N=159) | Obefazimod 50 mg (N=318) |
|---|---|---|---|
| Any TEAE | “77 (48.4%)” | “81 (50.9%)” | “194 (61.0%)” |
| TEAE leading to study drug discontinuation | “9 (5.7%)” | “8 (5.0%)” | “15 (4.7%)” |
| Serious TEAE | “7 (4.4%)” | “6 (3.8%)” | “6 (1.9%)” |
| Malignancy | “0 (0.0%)” | “0 (0.0%)” | “0 (0.0%)” |
| Serious or severe (grade 3 or higher) infections and opportunistic infections | “0 (0.0%)” | “0 (0.0%)” | “2 (0.6%)” |
Serious adverse events, all-cause mortality, and adverse event time frame in the posted results
| Event, affected/at risk (%) | ABX464 50 mg | ABX464 25 mg | Placebo |
|---|---|---|---|
| All-cause mortality | “0/318 (0.00%)” | “0/159 (0.00%)” | “0/159 (0.00%)” |
| Any serious adverse event | “6/318 (1.89%)” | “6/159 (3.77%)” | “7/159 (4.40%)” |
| Colitis ulcerative | “2/318 (0.63%)” | “2/159 (1.26%)” | “3/159 (1.89%)” |
| Pancreatitis acute | “0/318 (0.00%)” | “1/159 (0.63%)” | “1/159 (0.63%)” |
| Pneumonia | “1/318 (0.31%)” | “0/159 (0.00%)” | “0/159 (0.00%)” |
| Uveitis | “0/318 (0.00%)” | “1/159 (0.63%)” | “0/159 (0.00%)” |
| Lipase increased | “0/318 (0.00%)” | “1/159 (0.63%)” | “0/159 (0.00%)” |
| Acute coronary syndrome | “0/318 (0.00%)” | “0/159 (0.00%)” | “1/159 (0.63%)” |
Non-serious adverse events at a 5% reporting threshold in the posted results
| Event, affected/at risk (%) | ABX464 50 mg | ABX464 25 mg | Placebo |
|---|---|---|---|
| Any non-serious adverse event at 5% threshold | “115/318 (36.16%)” | “40/159 (25.16%)” | “32/159 (20.13%)” |
| Headache | “82/318 (25.79%)” | “23/159 (14.47%)” | “9/159 (5.66%)” |
| Nausea | “29/318 (9.12%)” | “11/159 (6.92%)” | “3/159 (1.89%)” |
| Lipase increased | “19/318 (5.97%)” | “2/159 (1.26%)” | “4/159 (2.52%)” |
| N-terminal prohormone brain natriuretic peptide increased | “7/318 (2.20%)” | “3/159 (1.89%)” | “11/159 (6.92%)” |
| Anaemia | “12/318 (3.77%)” | “6/159 (3.77%)” | “11/159 (6.92%)” |
Adverse events in the late-breaking abstract
“For ABTECT2, TEAEs occurred in 61.0%, 50.9%, and 48.4% for Obe‐50, Obe‐25, and PBO, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall rate of serious adverse events and treatment emergent adverse events (TEAEs) leading to study drug discontinuation for pts treated with Obe were similar to PBO.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: study limitations
- Duration and comparator: ABTECT-2 compared obefazimod 25 mg and 50 mg once daily with placebo for 8 weeks, with adverse events collected for up to 12 weeks, and has no active comparator. Durability is assessed only in the separate ABTECT Maintenance trial. The pooled ABTECT-1 and ABTECT-2 analyses, including all patient-reported outcome results, are recorded under ABTECT-1; no patient-reported outcome result specific to ABTECT-2 was identified.
- Primary endpoint by dose: the 50 mg dose met the primary endpoint (clinical remission 19.8% against 6.3% with placebo; difference 13.4%, p=0.0001). The 25 mg dose did not (11.3% against 6.3%; difference 5.1%, p=0.1034), so under the hierarchical testing scheme the p-values for its key secondary endpoints are nominal. The company states that a “slightly more severe and refractory population” was randomized to 25 mg in ABTECT-2 than in ABTECT-1; in the posted baseline data, 76 of 159 participants receiving 25 mg had a prior advanced therapy inadequate response and 103 had a Mayo endoscopic subscore of 3.
- Sources of the results: the results come from the ClinicalTrials.gov posting (first posted September 10, 2026), a congress abstract, and company press releases and filings. The posted results do not specify the analysis population for baseline characteristics or outcome measures.
- Population: participants were 16 years or older (18 or older in the EU, the EEA, Israel, Serbia, and Ukraine) with a modified Mayo Score of 5 or more and a centrally read endoscopic subscore of 2 or 3. Of 636 participants, 314 (49.4%) had a prior advanced therapy inadequate response and 72 had a prior inadequate response to a JAK inhibitor; 41 were 65 years or older and 13 were Black or African American. Randomization was also stratified by region (Japan or rest of world), and the registry lists 262 locations. The protocol excludes the region factor from the primary analysis model “for consistency with ABX464-105”.
- Background therapy: stable oral 5-ASA and oral corticosteroids were allowed in all arms, and the protocol states that such therapy “may be partially effective at controlling UC symptoms”.
- Subgroups: subgroup results by prior advanced therapy inadequate response come from small groups. Among participants with a prior inadequate response, clinical remission occurred in 4 of 76 (5.3%) receiving 25 mg and 4 of 79 (5.1%) receiving placebo (p=0.8529), and in 20 of 159 (12.6%) receiving 50 mg (p=0.0652).
- Safety reporting: serious adverse events occurred in 6 of 318 participants (1.89%) receiving 50 mg, 6 of 159 (3.77%) receiving 25 mg, and 7 of 159 (4.40%) receiving placebo. Non-serious lipase increase was reported in 19 of 318 (5.97%) receiving 50 mg and 4 of 159 (2.52%) receiving placebo, and serious acute pancreatitis in 1 participant receiving 25 mg and 1 receiving placebo.